Al Mayadeen English

  • Ar
  • Es
  • x
Al Mayadeen English

Slogan

  • News
    • Politics
    • Economy
    • Sports
    • Arts&Culture
    • Health
    • Miscellaneous
    • Technology
    • Environment
  • Articles
    • Opinion
    • Analysis
    • Blog
    • Features
  • Videos
    • NewsFeed
    • Video Features
    • Explainers
    • TV
    • Digital Series
  • Infographs
  • In Pictures
  • • LIVE
News
  • Politics
  • Economy
  • Sports
  • Arts&Culture
  • Health
  • Miscellaneous
  • Technology
  • Environment
Articles
  • Opinion
  • Analysis
  • Blog
  • Features
Videos
  • NewsFeed
  • Video Features
  • Explainers
  • TV
  • Digital Series
Infographs
In Pictures
  • Africa
  • Asia
  • Asia-Pacific
  • Europe
  • Latin America
  • MENA
  • Palestine
  • US & Canada
BREAKING
Israeli media: IOF's top lawyer hands in resignation over leak of Sde Teiman video
Al Mayadeen's correspondent: Israeli drone strike targets motorcycle in Kawnin, South Lebanon.
Hegseth in a meeting with his Chinese counterpart: Washington will continue to defend its interests vigorously
US Defense Secretary Pete Hegseth: The United States is concerned about China's activities in the South China Sea
Occupied Palestine: Israeli occupation forces demolishe residential homes east of Khan Younis city in the southern Gaza Strip
Al Mayadeen correspondent: An Israeli drone attacked the main road in the town of Harouf, South Lebanon.
Lebanese President: Israeli aggression on Blida took place in aftermath of meeting of ceasefire monitoring committee.
Lebanese President Joseph Aoun asks Commander of Lebanese Army to confront any Israeli incursion into liberated Lebanese territory in the South.
Al Mayadeen's correspondent: Israeli aircraft launch series of strikes on area of Jarmaq, South Lebanon.
Reuters: Afghanistan and Pakistan agree to restart peace talks in Istanbul.

FDA approval of Alzheimer's drug Aduhelm ‘rife with irregularities’

  • By Al Mayadeen English
  • Source: Agencies
  • 30 Dec 2022 10:24
3 Min Read

This comes against the backdrop of criticism as the FDA is expected to decide on approving another drug for treating the disease in January.

  • x
  • Probe: Alzheimer’s drug approval ‘rife with irregularities’
    Probe: Alzheimer’s drug approval ‘rife with irregularities’

Sources reported on Friday that the 2021 FDA's approval of an Alzheimer's drug called Aduhelm was "rife with irregularities" as an 18-month congressional investigation issued on Thursday found an "atypical collaboration" between FDA regulators and Aduhelm manufacturer, Biogen. 

According to the probe, investigators found that the company intended to "make history" when it set an "unjustifiably high" initial yearly price of $56,000 for the drug.

This comes against the backdrop of criticism as the FDA is expected to decide on approving another drug for treating the disease in January.

The report also found that there was an unusually high amount of phone exchanges between company officials and FDA delegates.

It also revealed that the company and the agency spent months preparing a report that did not account for substantial disagreement within the FDA about how to handle Aduhelm.

The report called on the agency to take "swift action" to make sure that any future approvals aren't met with "the same doubts about the integrity of FDA’s review."

Both the company and the FDA issued statements on Thursday to defend Aduhelm's approval process.

Biogen knew Aduhelm would dramatically affect Medicare. If just 250,000 patients got the drug, it would account for more than 25% of the Part B budget. If Aduhelm reached its full potential, it would cost taxpayers upward of $70 billion. pic.twitter.com/B2y46UrE95

— Damian Garde (@damiangarde) December 29, 2022

Related News

Alzheimer's drug approval optimistic amid promising results

UN report reveals cocaine in upward trend, meth market expands

Read more: Canada going as far as possible abuse with MAiD, hitting brakes needed

The FDA approved Aduhelm in 2021 under accelerated approval over the objections of its independent scientific advisors who felt the data failed to prove the drug's benefit to patients.

The company had reportedly halted two studies after results suggested that the drug wasn't giving the desired effects: slowing Alzheimer's deteriorating process. 

The FDA said the drug was efficient on the grounds that it reduced a buildup of plaque in the brain.

But three of the agency's advisors resigned in protest of these claims and the agency's then-acting chief was called for questioning. 

Medicare eventually declined to fund the drug, even after the yearly price was reduced to $28,000.

In a statement Thursday, FDA said its "decision to approve Aduhelm was based on our scientific evaluation of the data contained in the application, which is described in the approval materials. ... That said, the agency has already started implementing changes consistent with the Committee's recommendations."

On Biogen's part, it said "Alzheimer’s is a highly complex disease and we have learned from the development and launch of Aduhelm,” but that it “stands by the integrity of the actions we have taken."

Read more: Scientists develop new blood test for Alzheimer’s disease

  • Drug
  • Alzheimer's Disease

Most Read

Arab League chief exposes secret US deal shielding 'Israel’s' nukes

Arab League chief exposes secret US deal shielding 'Israel’s' nukes

  • Politics
  • 27 Oct 2025
Hi-tech holocaust: Microsoft’s role in Gaza genocide

Microsoft's role in world’s first AI-driven genocide, in Gaza, exposed

  • Technology
  • 28 Oct 2025
What Marr evidently didn't seem to understand was that Hedges isn't saying that Western journalists manipulate the truth, but that they systematically amplify Israeli narratives they know are false. (Al Mayadeen English; Illustrated by Batoul Chamas)

Western journalists know they have a case to answer for their betrayal of Gaza, and it frightens them

  • Opinion
  • 24 Oct 2025
Sheikh Naim Qassem speaks during an interview with Al-Manar TV, October 26, 2025 (Screenshot)

Hezbollah ready to face 'Israel' in case of war: Sheikh Naim Qassem

  • Politics
  • 27 Oct 2025

Coverage

All
War on Gaza

Read Next

All
ap
Politics

Hamas calls on int’l community to act against Israeli settlement plan

In this Nov. 9, 2017, file photo, U.S. President Donald Trump, right, chats with Chinese President Xi Jinping during a welcome ceremony at the Great Hall of the People in Beijing. (AP)
Economy

Ex-US diplomat says Trump-Xi deal 'tactical retreat', not lasting deal

An unarmed Minuteman II intercontinental ballistic missile launches from Vandenberg Air Force Base, California, during a test in 2002. (US Air Force)
Politics

JD Vance defends Trump's nuclear test plan as 'crucial for security'

Ultra-Orthodox Jews attend the "million man" protest against military conscription, in occupied al-Quds, October 30, 2025 (AFP)
Politics

Haredi mass rally in al-Quds exposes Zionist regime's growing crisis

Al Mayadeen English

Al Mayadeen is an Arab Independent Media Satellite Channel.

All Rights Reserved

  • x
  • Privacy Policy
  • About Us
  • Contact Us
  • Authors
Android
iOS